Andrew Fenton - Zoetis President

<div class='circular--portrait' style='background:#2A0CD0;color: white;font-size:3em;padding-top: 35px;;'>ZTS</div>
ZTS -- USA Stock  

Earning Report: February 13, 2020  

Mr. Andrew Fenton is Executive Vice President and Chief Digital and Technology Officer of the Company
Age: 54  President Since 2018      
973 822-7000
Fenton has served as our Executive Vice President and Chief Digital and Technology Officer since December 2018, having previously served as Executive Vice President and Chief Information Officer from August 2016 to December 2018 and having joined Zoetis as Senior Vice President and CIO in 2014. From November 2013 to September 2014, Mr. Fenton was a partner and principal with EY in the Life Sciences practice supporting CIO Transformation Services, and from October 2005 to November 2013, he was Senior Vice President and CIO of Warner Chilcott. He has also held senior positions at IBM Global Services and at PricewaterhouseCoopers in the Pharmaceutical Practice.

Andrew Fenton Latest Insider Activity

Andrew Fenton over three months ago via Macroaxis 
Zoetis exotic insider transaction detected

Management Efficiency

The company has 6.66 B in debt with debt to equity (D/E) ratio of 248.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.3 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Douglas BoothePerrigo Company Plc
Saumen ChakrabortyDr Reddys Laboratories Ltd
Charles MilsteinVertex Pharmaceuticals Incorpor
James MichaudPerrigo Company Plc
Jay MarkowitzRegeneron Pharmaceuticals
John HendricksonPerrigo Company Plc
John GrayVertex Pharmaceuticals Incorpor
Marion McCourtRegeneron Pharmaceuticals
Ganadhish KamatDr Reddys Laboratories Ltd
Sripada ChandrasekharDr Reddys Laboratories Ltd
Marc CouckePerrigo Company Plc
Peter PowchikRegeneron Pharmaceuticals
Daniel PlewRegeneron Pharmaceuticals
Joseph LaRosaRegeneron Pharmaceuticals
Reshma KewalramaniVertex Pharmaceuticals Incorpor
James DillardPerrigo Company Plc
Svend AndersenPerrigo Company Plc
Paul WeningerPerrigo Company Plc
Paul SilvaVertex Pharmaceuticals Incorpor
Douglas McCorkleRegeneron Pharmaceuticals
Umang VohraDr Reddys Laboratories Ltd

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run Portfolio Comparator Now


Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Also Currentnly Active

Purchased over 30 shares of
a day ago
Traded for 80.1
Purchased over 300 shares of
a day ago
Traded for 9.16
Purchased over 50 shares of
a day ago
Traded for 58.39
See also Your Current Watchlist. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.